Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19FN4O4.ClH |
| Molecular Weight | 398.817 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN(CC1)C2=C3OCN(C)N4C=C(C(O)=O)C(=O)C(C=C2F)=C34
InChI
InChIKey=OCRYFLKYXNBUEY-UHFFFAOYSA-N
InChI=1S/C17H19FN4O4.ClH/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25;/h7-8H,3-6,9H2,1-2H3,(H,24,25);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H19FN4O4 |
| Molecular Weight | 362.3556 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats. | 2010-05 |
|
| Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta). | 2009-10 |
|
| Fully automatic sample treatment by integration of microextraction by packed sorbents into commercial capillary electrophoresis-mass spectrometry equipment: application to the determination of fluoroquinolones in urine. | 2009-04-15 |
|
| Single- and multiple-dose pharmacokinetics of marbofloxacin after oral administration to rabbits. | 2009-04 |
|
| Are liquid chromatography/electrospray tandem quadrupole fragmentation ratios unequivocal confirmation criteria? | 2009-04 |
|
| Resolution of tongue lesions caused by Leishmania infantum in a dog treated with the association miltefosine-allopurinol. | 2009-03-26 |
|
| Simultaneous determination of 13 quinolones in eggs using column high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry and depletion of pefloxacin methanesulfonate in eggs. | 2009-02-11 |
|
| Water-compatible molecularly imprinted polymer for the selective recognition of fluoroquinolone antibiotics in biological samples. | 2009-01 |
|
| Simultaneous determination of quinolone antibacterials in bovine milk by liquid chromatography-mass spectrometry. | 2008-11 |
|
| Tissue distribution of marbofloxacin after 'systemic' administration into the isolated perfused bovine udder. | 2008-10 |
|
| Influence of systemic fluoroquinolone administration on the presence of Pasteurella multocida in the upper respiratory tract of clinically healthy calves. | 2008-09-22 |
|
| Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. | 2008-09-18 |
|
| Development of an immunochromatography strip for the rapid detection of 12 fluoroquinolones in chicken muscle and liver. | 2008-07-23 |
|
| Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. | 2008-07 |
|
| [Multiresidue determination of quinolones in animal and fishery products by HPLC]. | 2008-06 |
|
| Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. | 2008-05-31 |
|
| In-line solid-phase extraction preconcentration in capillary electrophoresis-tandem mass spectrometry for the multiresidue detection of quinolones in meat by pressurized liquid extraction. | 2008-05 |
|
| Improved determination of quinolones in milk at their MRL levels using LC-UV, LC-FD, LC-MS and LC-MS/MS and validation in line with regulation 2002/657/EC. | 2008-04-14 |
|
| Marbofloxacin for the treatment of experimentally induced Mycoplasma haemofelis infection in cats. | 2008-03-04 |
|
| Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis. | 2008-03 |
|
| Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. | 2007-12 |
|
| Multiresidue method for simultaneous determination of quinolone antibacterials in pig kidney samples by liquid chromatography with fluorescence detection. | 2007-11-15 |
|
| Susceptibility of Pseudomonas isolates from the ears and skin of dogs to enrofloxacin, marbofloxacin, and ciprofloxacin. | 2007-11-03 |
|
| Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis. | 2007-11-03 |
|
| Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. | 2007-11 |
|
| Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. | 2007-10 |
|
| Comparative quantification of the in vitro activity of veterinary fluoroquinolones. | 2007-09-20 |
|
| Pulmonary function and antimicrobial concentration after marbofloxacin inhalation in horses. | 2007-09-08 |
|
| Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic integration of marbofloxacin after subcutaneous administration in goats. | 2007-09 |
|
| Pharmacokinetics of a single intravenous dose of marbofloxacin in adult donkeys. | 2007-07-28 |
|
| [Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry]. | 2007-07 |
|
| Single-dose pharmacokinetics of marbofloxacin in Egyptian buffalo (Bubalus bubalis L.) steers. | 2007-06-09 |
|
| In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals. | 2007-06 |
|
| Separation of fifteen quinolones by high performance liquid chromatography: application to pharmaceuticals and ofloxacin determination in urine. | 2007-06 |
|
| Identification and comparison of marbofloxacin metabolites from the plasma of ball pythons (Python regius) and blue and gold macaws (Ara ararauna). | 2007-06 |
|
| Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves. | 2007-06 |
|
| Simultaneous determination of trace levels of 10 quinolones in swine, chicken, and shrimp muscle tissues using HPLC with programmable fluorescence detection. | 2007-05-16 |
|
| Stability of frozen stock solutions of beta-lactam antibiotics, cephalosporins, tetracyclines and quinolones used in antibiotic residue screening and antibiotic susceptibility testing. | 2007-03-14 |
|
| Microbiological detection of 10 quinolone antibiotic residues and its application to artificially contaminated poultry samples. | 2007-03 |
|
| Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals. | 2007-02-01 |
|
| Determination of fluoroquinolones in milk samples by postcolumn derivatization liquid chromatography with luminescence detection. | 2006-12-27 |
|
| Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. | 2006-12-26 |
|
| Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. | 2006-12 |
|
| Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. | 2006-12 |
|
| Multiresidue method for the determination of quinolone antibiotics in bovine raw milk by capillary electrophoresis-tandem mass spectrometry. | 2006-11-15 |
|
| Effect of chronic FIV infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection. | 2006-10-31 |
|
| Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. | 2006-10 |
|
| Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. | 2006-10 |
|
| Preliminary single-dose pharmacokinetics of marbofloxacin in ball pythons (Python regius). | 2006-03 |
|
| Inclusion of marbofloxacin in PMMA orthopaedic cement: an in vitro experimental study. | 2006 |
Patents
Sample Use Guides
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
Route of Administration:
Other
MIC50 values of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs were: Staphylococcus intermedius - 0.25 ug/ml, Escherichia coli - 0.03 ug/ml, Proteus mirabilis - 0.06 ug/ml, Beta-hemolytic Streptococcus, (not Group A or Group B) - 1 ug/ml, Streptococcus, Group D enterococcus - 1 ug/ml, Pasteurella multocida - 0.015 ug/ml, Staphylococcus aureus - 0.25 ug/ml, Enterococcus faecalis - 2 ug/ml, Klebsiella pneumoniae - 0.06 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 17:10:39 GMT 2025
by
admin
on
Wed Apr 02 17:10:39 GMT 2025
|
| Record UNII |
W3C3ZZ8R2D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
115551-26-3
Created by
admin on Wed Apr 02 17:10:39 GMT 2025 , Edited by admin on Wed Apr 02 17:10:39 GMT 2025
|
PRIMARY | |||
|
14576609
Created by
admin on Wed Apr 02 17:10:39 GMT 2025 , Edited by admin on Wed Apr 02 17:10:39 GMT 2025
|
PRIMARY | |||
|
W3C3ZZ8R2D
Created by
admin on Wed Apr 02 17:10:39 GMT 2025 , Edited by admin on Wed Apr 02 17:10:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
